Banco Bilbao Vizcaya Argentaria S.A. Takes $463,000 Position in Liquidia Technologies, Inc. $LQDA

Key Points

• Banco Bilbao Vizcaya Argentaria S.A. has acquired a new position in Liquidia Technologies, purchasing 30,000 shares valued at approximately $463,000 in the first quarter.
• Insider trading activity shows significant sales, with General Counsel Russell Schundler selling 7,836 shares, representing a 1.34% decrease in his holdings.
• Liquidia Technologies reported a **141.5% increase** in quarterly revenue compared to the previous year, although it missed earnings expectations with a loss of ($0.49) EPS.

Banco Bilbao Vizcaya Argentaria S.A. purchased a new stake in Liquidia Technologies, Inc. (NASDAQ:LQDA - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 30,000 shares of the company's stock, valued at approximately $463,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Wellington Management Group LLP grew its position in shares of Liquidia Technologies by 9.0% in the first quarter. Wellington Management Group LLP now owns 196,226 shares of the company's stock valued at $2,894,000 after purchasing an additional 16,227 shares during the last quarter. Kovitz Investment Group Partners LLC acquired a new stake in shares of Liquidia Technologies in the first quarter valued at about $384,000. Nuveen LLC acquired a new stake in shares of Liquidia Technologies in the first quarter valued at about $2,642,000. Aigen Investment Management LP acquired a new stake in shares of Liquidia Technologies in the first quarter valued at about $151,000. Finally, CenterBook Partners LP bought a new stake in shares of Liquidia Technologies in the first quarter valued at about $1,786,000. 64.54% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Liquidia Technologies news, insider Scott Moomaw sold 4,797 shares of the firm's stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $14.28, for a total transaction of $68,501.16. Following the completion of the transaction, the insider owned 223,231 shares in the company, valued at $3,187,738.68. This trade represents a 2.10% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Rajeev Saggar sold 5,327 shares of the firm's stock in a transaction dated Monday, July 14th. The stock was sold at an average price of $14.28, for a total transaction of $76,069.56. Following the transaction, the insider owned 271,413 shares of the company's stock, valued at approximately $3,875,777.64. This represents a 1.92% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 90,277 shares of company stock valued at $1,469,392. 26.50% of the stock is owned by company insiders.

Liquidia Technologies Price Performance

LQDA traded down $0.44 during midday trading on Friday, reaching $27.02. 456,495 shares of the company's stock were exchanged, compared to its average volume of 1,794,149. The firm has a market capitalization of $2.33 billion, a price-to-earnings ratio of -15.91 and a beta of 0.14. The company has a quick ratio of 2.41, a current ratio of 2.49 and a debt-to-equity ratio of 9.84. Liquidia Technologies, Inc. has a one year low of $8.75 and a one year high of $28.82. The business has a 50-day simple moving average of $18.60 and a two-hundred day simple moving average of $16.28.

Liquidia Technologies (NASDAQ:LQDA - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.06). The business had revenue of $8.84 million for the quarter, compared to the consensus estimate of $3.90 million. Liquidia Technologies had a negative return on equity of 232.96% and a negative net margin of 732.17%.The business's revenue for the quarter was up 141.5% compared to the same quarter last year. As a group, research analysts predict that Liquidia Technologies, Inc. will post -1.51 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Scotiabank increased their target price on shares of Liquidia Technologies from $36.00 to $37.00 and gave the company a "sector outperform" rating in a research note on Wednesday, May 28th. Wells Fargo & Company increased their target price on shares of Liquidia Technologies from $25.00 to $31.00 and gave the company an "overweight" rating in a research note on Wednesday, August 13th. Raymond James Financial increased their target price on shares of Liquidia Technologies from $33.00 to $41.00 and gave the company a "strong-buy" rating in a research note on Wednesday, August 13th. Bank of America reduced their target price on shares of Liquidia Technologies from $25.00 to $23.00 and set a "buy" rating for the company in a research note on Wednesday, June 11th. Finally, Jefferies Financial Group assumed coverage on shares of Liquidia Technologies in a research note on Friday, August 15th. They issued a "buy" rating and a $43.00 target price for the company. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $32.11.

About Liquidia Technologies

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).